Loading
A phase 1/2 trial of IBI354 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05636215 by Innovent Biologics (Suzhou) Co. Ltd., with 368 participants planned, started 2023-04-04 and due to reach its primary completion in 2025-04-30. Interventions recorded: IBI354.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Innovent Biologics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Innovent Biologics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Innovent Biologics and the tag pipeline.
Shares IBI354, Innovent Biologics.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/